NPPA fixes separate ceiling prices for drugs with special features, Details
Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of Mannitol and Metronidazole Injection as part of fixation of ceiling price of scheduled formulations under the revised Schedule I of Drugs (Prices Control) Order, 2013.In the 108th meeting of the Authority under the DPCO, 2013, held on January 27, under the Chairmanship of Kamlesh Kumar Pant, Chairman...
Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of Mannitol and Metronidazole Injection as part of fixation of ceiling price of scheduled formulations under the revised Schedule I of Drugs (Prices Control) Order, 2013.
In the 108th meeting of the Authority under the DPCO, 2013, held on January 27, under the Chairmanship of Kamlesh Kumar Pant, Chairman of NPPA, the Authority considered fixing the ceiling prices of the formulations listed in the Schedule I of the DPCO, 2013, after it has revised the Schedule replacing the National List of Essential Medicines (NLEM), 2015 with the latest NLEM, 2022.
The Authority approved separate ceiling prices for Mannitol injection 20% and metronidazole injection 500mg/100 ml from three companies namely Otsuka Pharmaceuticals Pvt Ltd, Denis Chem Lab Ltd and Rusoma Laboratories Pvt Ltd, by adding 15 per cent over the ceiling prices refixed under the NLEM 2022 considering the special features of these formulations.
For Mannitol injection 20%, the Authority had fixed separate ceiling prices adding 15 per cent over the normal ceiling prices in a meeting held on August 18, 2021 based on the NLEM, 2015 and the latest decision is to revise the separate ceiling price based on the NLEM, 2022.
The Authority noted that based on the recommendation of MDC in its 35th Meeting held on 18.08.2021, separate ceiling prices were approved by the Authority in its 92nd meeting for three companies i.e. Otsuka Pharmaceuticals Pvt. Limited, Denis Chem Lab Ltd. and Rusoma Laboratories Pvt. Ltd. for the following two formulations by adding 15% over the normal ceiling prices for having the special features. Their prevailing ceiling prices under NLEM 2015 are as given below;
Ceiling prices fixed for three companies for two formulations
S.No. | Formulation | Normal Ceiling | Separate Ceiling Price for |
| 1. | Mannitol Injection 20% | Rs. 0.33/ML | Rs.0.382/ML |
2. | Metronidazole Injection 500mg/100m1 | Rs. 0.22/ML | Rs. 0.25 /ML |
As the prices of above two formulations have been refixed under NLEM 2022 in the 107th meeting, the Authority deliberated upon the matter and approved the following ceiling prices for Otsuka Pharma, Denis Chem Lab Ltd. and Rusoma Laboratories Pvt. Ltd. for following two formulations by adding 15% over the ceiling prices refixed under NLEM 2022 on account of the special features, as given below;
Ceiling Price on account of special features
S.No. | Formulation | Normal | Notification | Separate Ceiling |
1 | Mannitol Injection 20% | Rs. 0.31/ML | S.O. 194(E) | Rs. 0.36/ML |
2 | Metronidazole Inejction 500mg/100m1 | Rs. 0.19/ML | Rs. 0.22/ML |
The authority also noted that if any company other than these, intends to launch the said formulations with special feature as mentioned above, it shall apply to NPPA for separate ceiling price.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd